Home
De nobis
De nobis
Testimonium
Officina
Salus et Environmental Praesidium
Products
Product Category
Active Pharmaceutical Ingredient (API)
Iguratimod
Apremilast
Bromhexine HCl
Citrate Tofacitinib
Urapidil hydrochloride
Allium
Celecoxib
Dexmedetomidine Hydrochloridis
Rocuronium Bromide
Lifitegrast
Diphelikephalin
Gemcitabine HCl
Pharmaceutical Medium
Gemcitabine HCl T9
Gemcitabine HCl T8
Gemcitabine HCl T6
Gemcitabine HCl T3
Tetrazole
1H-tetrazole
5-amino Tetrazole
Iminazoles
4,5-Dicyanoimidazole
Pyridine
2,6-Diaminopyridine
Heterocyclics
4-Nitrobenzoic Acid
News
Blog
Company News
Industria News
R&D
Mitte Inquisitionem
Nobis loquere
Latine
English
Español
Português
русский
Français
日本語
Deutsch
tiếng Việt
Italiano
Nederlands
ภาษาไทย
Polski
한국어
Svenska
magyar
Malay
বাংলা ভাষার
Dansk
Suomi
हिन्दी
Pilipino
Türkçe
Gaeilge
العربية
Indonesia
Norsk
تمل
český
ελληνικά
український
Javanese
فارسی
தமிழ்
తెలుగు
नेपाली
Burmese
български
ລາວ
Latine
Қазақша
Euskal
Azərbaycan
Slovenský jazyk
Македонски
Lietuvos
Eesti Keel
Română
Slovenski
मराठी
Srpski језик
Sitemap
Home
De nobis
De nobis
|
Testimonium
|
Officina
|
Salus et Environmental Praesidium
Products
Product Category
Active Pharmaceutical Ingredient (API)
Iguratimod
CAS#123663-49-0
|
Arthritis Iguratimod
|
Arthritis rheumatica Iguratimod
|
CAS NO.123663-49-0
|
CAS 123663-49-0
|
123663-49-0
|
N-(3-Formamido-4-oxo-6-phénoxy-4H-chromen-7-yl) methanesulfonamide N-[7-(Methanesulfonamido) -4-oxo-6-phenoxy-4H-chromen-3-yl]
|
Iguratimod API
Apremilast
CAS#608141-41-9
|
CAS NO. 608141-41-9
|
CAS 608141-41-9
|
608141-41-9
|
TABULA Psoriasis Apremilast
|
(+)-N-[2-[1(S)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4 -yl]acetamide
|
Apremilast API
Bromhexine HCl
CAS#611-75-6
|
2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine hydrochloride
|
N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine Hydrochloridis
|
CAS NO.611-75-6
|
CAS 611-75-6
|
611-75-6
|
Bromhexine Hydrochloride API
|
Bromhexine HCl API
Citrate Tofacitinib
CAS#540737-29-9
|
(3R,4R) -4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino) propanetricarboxylate
|
CAS NO.540737-29-9
|
CAS 540737-29-9
|
540737-29-9
|
Tofacitinib Citrate API
Urapidil hydrochloride
CAS#64887-14-5
|
6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione
|
6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione Hydrochloridis
|
CAS NO.64887-14-5
|
CAS 64887-14-5
|
64887-14-5
|
Urapidil hydrochloride API
Allium
Diallyl Trisulfide
|
CAS#2050-87-5
|
CAS NO.2050-87-5
|
CAS 2050-87-5
|
2050-87-5
|
Allium Oil
Celecoxib
CAS#169590-42-5
|
Ostarthritis Celecoxib
|
CAS NO.169590-42-5
|
CAS 169590-42-5
|
169590-42-5
|
Celecoxib API
Dexmedetomidine Hydrochloridis
4-[(1r) -1-(2,3-dimethylphenyl)ethyl] -3h-imidazole hydrochloride
|
4-[(1r) -1-(2,3-dimethylphenyl)ethyl]3h-imidazole
|
CAS#145108-58-3
|
CAS NO.145108-58-3
|
CAS 145108-58-3
|
145108-58-3
|
Dexmedetomidine HCl API
|
Dexmedetomidine Hydrochloridis API
Rocuronium Bromide
CAS#119302-91-9
|
CAS NO.119302-91-9
|
CAS 119302-91-9
|
119302-91-9
|
Rocuronium Bromide API
Lifitegrast
CAS#1025967-78-5
|
CAS NO.1025967-78-5
|
CAS 1025967-78-5
|
1025967-78-5
|
Lifitegrast API
Diphelikephalin
4-Piperidinecarboxylic Acidum
|
1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) -4-aminopiperidine-4-acidi carboxylici
|
CAS#1024828-77-0
|
CAS NO.1024828-77-0
|
CAS 1024828-77-0
|
1024828-77-0
Gemcitabine HCl
Anti-tumor Gemcitabine
|
4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl] -1h-pyrimidin-2-one hydrochloride
|
CAS#122111-03-9
|
CAS NO.122111-03-9
|
CAS 122111-03-9
|
122111-03-9
|
Gemcitabinum hydrochloridum API
|
Gemcitabine HCl API
|
Gemcitabinum hydrochloridum
Pharmaceutical Medium
Gemcitabine HCl T9
CAS#134790-39-9
|
CAS NO.134790-39-9
|
CAS 134790-39-9
|
134790-39-9
|
Gemcitabine T9
Gemcitabine HCl T8
CAS#122111-11-9
|
CAS NO.122111-11-9
|
CAS 122111-11-9
|
122111-11-9
|
Gemcitabine T8
Gemcitabine HCl T6
CAS#122111-01-7
|
CAS NO.122111-01-7
|
CAS 122111-01-7
|
122111-01-7
|
Gemcitabine T6
Gemcitabine HCl T3
CAS#95058-92-7
|
CAS NO.95058-92-7
|
CAS 95058-92-7
|
95058-92-7
|
Gemcitabine T3
Tetrazole
1H-tetrazole
CAS NO.288-94-8
|
CAS 288-94-8
|
CAS#288-94-8
|
288-94-8
5-amino Tetrazole
CAS NO.4418-61-5
|
CAS 4418-61-5
|
CAS#4418-61-5
|
4418-61-5
Iminazoles
4,5-Dicyanoimidazole
CAS NO.1122-28-7
|
CAS 1122-28-7
|
CAS#1122-28-7
|
1122-28-7
|
Imidazole-4,5-dicarbonitrile
|
4,5-Dicyanoimidazole DCI
Pyridine
2,6-Diaminopyridine
CAS NO.141-86-6
|
CAS 141-86-6
|
CAS#141-86-6
|
141-86-6
Heterocyclics
4-Nitrobenzoic Acid
CAS NO.62-23-7
|
CAS 62-23-7
|
CAS#62-23-7
|
62-23-7
News
Blog
Estne V-amino Tetrazole
|
Quae sunt proprietates 1H-tetrazoli?
|
Quae sunt latus effectus utendi 2,6-Diaminopyridine?
|
What is the cost of Gemcitabine HCl T3 and is it covered by insurance?
|
An ullae probationes clinicae praesto sunt pro Gemcitabine HCl T6?
|
Gemcitabine HCl T8 quomodo aegris ministratur?
|
Suntne aliquae curationes in Gemcitabine HCl T9 pro aegris cancri?
|
Quid sunt usus 4,5-Dicyanoimidazole?
|
Quid est 4-Acidum Nitrobenzoicum et ejus usus?
|
Quod Urapidil Hydrochloride
|
Quomodo Dexmedetomidine hydrochloridis systematis cardiovascularibus afficit?
|
Quid latus effectus Rocuronii Bromide?
|
Quid latus effectus
|
Quod commendatur dosis
|
Quae sunt optimae rationes incorporandi Garlicin
Company News
2023CPHI Barcinonensis
|
Congregate ad novum capitulum
|
Vires fabricandi praemisit|Jiangsu Runan Pharmaceutical Co.,LTD annui conventus & commendationis conventus
|
2024CPHI Japan
|
Praecipua exercitatio practica pro accidentibus lacus lacus in logistics societatis anno 2024
|
2023API Exhibition
|
Oratio in Provectus Usus Exchange Conference of Jiangsu Runan Pharmaceutical on Enterprise Safety Production in Industrial Parks
|
Comprehensiva practica ad productionem salutis accidentia in MMXXIII
|
Notitia Approbatio pro Fusce Trials Classis 1 Medicamenta innovativa per Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd.
|
Jiangsu Run'an Pharmaceutical Co., Ltd. Salutis Productio Mensis Actio Summarium, Aestimatio, Praemium et Commendatio Notitia
|
Jiangsu Runan Pharmaceutical recipit GMP inspectionem
|
Confirma proprietatem intellectualem tutelam et creo amet agro
|
Chen Zhichang, Secretarius Factionis Municipalis Committee, investigationes perduxit de constructione novae areae officinae Zhengda Qingjiang Pharmaceuticae.
|
Nuntiatio Jiangsu Run'an Pharmaceutical Co., Ltd. ante MMXXIII Tersus Productio Audit
|
Sodium nitroprussidum et urapidil, medicamenta antihypertensiva, diversas habent contraindicationes et motus adversas!
|
Notae pharmacologicae dexmedetomidine eiusque applicatione in delirio postopertivo in aegros senes
|
Quis efficacior est, Elamod vel Methotrexate
|
2024 CPHI CHINA Shanghai
Industria News
Lifitegrast
|
Difelikefalin-Prima medicamentum probatum FDA ad curationem morbi renis longi (CKD) iniectio pruritus-Difelikefalin
|
Commoda Tetrazole
R&D
Mitte Inquisitionem
Nobis loquere
Wangjing
Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.
Privacy Policy
Reject
Accept